Filing Flows › 60 Degrees Pharmaceuticals (SXTP) › Q1 2026
60 Degrees Pharmaceuticals (SXTP) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 15, 2026
60 Degrees Pharmaceuticals (SXTP) reported revenue of $162K for the first quarter 2026 (Q1 2026), -0.9% from a year earlier and -47% from the quarter before.
60 Degrees Pharmaceuticals, Q1 2026: revenue $162K (-0.9% year over year), net loss $2.1M, operating cash flow −$2.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $162K | -47% | -0.9% |
| Operating profit | −$2.1M | — | — |
| Net earnings | −$2.1M | — | — |
| Operating cash flow | −$2.7M | — | — |
What changed
Revenue was $162K in Q1 2026, down 1% year over year and down 47% from the previous quarter.
Gross margin was 47.1%, down 8.1 points from Q1 2025. Operating costs exceeded revenue by $2.1M, an operating margin of -1292.5%. Operating expenses grew 9% against a revenue fall of 1%. The quarter ended with a net loss of $2.1M, wider than the previous quarter's $1.4M loss. Minority interests bore $1K of it: to shareholders the quarter was a loss of $2.1M.
Operating cash flow was −$2.7M. Non-cash charges added back $26K of depreciation and amortization and $124K of share-based compensation. Working capital and other items used $801K. Capital expenditures of $30K exceeded it, leaving free cash flow of −$2.8M.
Questions
What was 60 Degrees Pharmaceuticals' revenue in the first quarter 2026?
60 Degrees Pharmaceuticals (SXTP) reported revenue of $162K for the first quarter 2026 (Q1 2026), -0.9% from a year earlier and -47% from the quarter before.